AstraZeneca admitted Seroquel-diabetes link in Japan, then denied it in U.S.

An AstraZeneca saleswoman told a U.S. doctor the antipsychotic Seroquel didn’t cause diabetes almost four years after the company warned Japanese physicians about the drug’s links to the disease, internal documents show.

Nancy White, the saleswoman, and a colleague met in July 2006 with an unidentified doctor who reported “getting a lot of flak” from patients about Seroquel’s diabetes links, according to a note unsealed as part of a lawsuit. AstraZeneca wrote in November 2002 to Japanese doctors that it received a dozen reports of diabetes-related cases tied to Seroquel “where causality with the drug could not be ruled out.”

White said in the 2006 note that she told the physician that “there has been no causative effect” found between Seroquel and diabetes. The doctor “said he would not quit writing” prescriptions for Seroquel “due to this at this time,” White reported.

More than 15,000 patients have sued London-based AstraZeneca, claiming the company withheld information about links between diabetes and Seroquel. Many of the suits also claim AstraZeneca promoted Seroquel, approved by the U.S. Food and Drug Administration for schizophrenia and bipolar disorder, for unapproved uses.

A federal judge in Orlando, Florida, ordered AstraZeneca to unseal the sales-call notes by Sept. 11 after Bloomberg News filed a motion to gain access to company files turned over in Seroquel litigation. The judge allowed AstraZeneca to withhold physicians’ names on privacy grounds.

All federal-court cases over Seroquel, a so-called atypical or second-generation anti-psychotic medicine, have been consolidated in Orlando for pre-trial proceedings.

More at Bloomberg